EUVIMEDOpdag EUVIMED
Open access

Identification of a Selective Pharmacologic IRE1/XBP1s Activator with Enhanced Tissue Exposure

Jie Sun, Kyunga Lee, Sergei Kutseikin, Adrian Guerrero, Bibiana Rius, Aparajita Madhavan, Chavin Buasakdi, Ka-Neng Cheong iD, Priyadarshini Chatterjee, Dorian A Rosen, Leonard Yoon iD, Maziar S Ardejani and 5 more

ACS Chemical Biology · 2025

DOI: 10.1021/acschembio.4c00867 ↗

At a glance

Journal article in ACS Chemical Biology, 2025. Written by Jie Sun and 16 co-authors. Institution: Department of Molecular and Cellular Biology, Scripps Research, La Jolla, California 92037, United States. Major MEDLINE topics: X-Box Binding Protein 1, Protein Serine-Threonine Kinases, Endoribonucleases. Cited 6 times so far (Crossref); 53 references. The full text is freely available in PubMed Central. Funded by: NIA NIH HHS, NIDDK NIH HHS, American Diabetes Association.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Activation of the IRE1/XBP1s signaling arm of the unfolded protein response (UPR) has emerged as a promising strategy to mitigate etiologically diverse diseases. Despite this promise, few compounds are available to selectively activate IRE1/XBP1s signaling to probe the biologic and therapeutic implications of this pathway in human disease. Recently, we identified the compound IXA4 as a highly selective activator of protective IRE1/XBP1s signaling. While IXA4 has proven useful for increasing IRE1/XBP1s signaling in cultured cells and mouse liver, the utility of this compound is restricted by its limited activity in other tissues. To broaden our ability to pharmacologically interrogate the impact of IRE1/XBP1s signaling in vivo, we sought to identify IRE1/XBP1s activators with greater tissue activity than IXA4. We reanalyzed 'hits' from the high throughput screen used to identify IXA4, selecting compounds from structural classes not previously pursued. We then performed global RNAseq to confirm that these compounds showed transcriptome-wide selectivity for IRE1/XBP1s activation. Functional profiling revealed compound IXA62 as a selective IRE1/XBP1s activator that reduced Aβ secretion from CHO7PA2 cells and enhanced glucose-stimulated insulin secretion from rat insulinoma cells, mimicking the effects of IXA4 in these assays. IXA62 robustly and selectively activated IRE1/XBP1s signaling in the liver of mice dosed compound intraperitoneally or orally. In treated mice, IXA62 showed broader tissue activity, relative to IXA4, inducing expression of IRE1/XBP1s target genes in additional tissues such as kidney and lung. Collectively, our results designate IXA62 as a selective IRE1/XBP1s signaling activating compound with enhanced tissue activity, which increases our ability to pharmacologically probe the biologic significance and potential therapeutic utility of enhancing adaptive IRE1/XBP1s signaling in vivo.

Subjects

MeSH terms (MEDLINE)

X-Box Binding Protein 1Protein Serine-Threonine KinasesEndoribonucleasesAnimalsHumansMiceUnfolded Protein ResponseSignal TransductionRatsHigh-Throughput Screening Assays

Substances

X-Box Binding Protein 1Protein Serine-Threonine KinasesEndoribonucleasesERN1 protein, humanXBP1 protein, humanXbp1 protein, mouse

Authors and institutions

  • Department of Molecular and Cellular Biology, Scripps Research, La Jolla, California 92037, United States.
  • Department of Chemistry, Scripps Research, La Jolla, California 92037, United States.
  • Department of Immunology and Microbial Science, Scripps Research, La Jolla, California 92037, United States.
  • The Skaggs Institute for Chemical Biology, Scripps Research, La Jolla, California 92037, United States.

ORCID profiles: Ka-Neng Cheong, Leonard Yoon, Jeffery W Kelly, R Luke Wiseman

Funding

  • NIA NIH HHS
  • NIDDK NIH HHS
  • American Diabetes Association
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute on Aging

Cite

APA

Sun, J., Lee, K., Kutseikin, S., Guerrero, A., Rius, B., Madhavan, A., Buasakdi, C., Cheong, K. N., Chatterjee, P., Rosen, D. A., Yoon, L., Ardejani, M. S., Mendoza, A., Rosarda, J. D., Saez, E., Kelly, J. W., & Wiseman, R. L. (2025). Identification of a Selective Pharmacologic IRE1/XBP1s Activator with Enhanced Tissue Exposure. ACS Chemical Biology. https://doi.org/10.1021/acschembio.4c00867

Vancouver

Sun J, Lee K, Kutseikin S, Guerrero A, Rius B, Madhavan A, et al. Identification of a Selective Pharmacologic IRE1/XBP1s Activator with Enhanced Tissue Exposure. ACS Chemical Biology. 2025. doi:10.1021/acschembio.4c00867

BibTeX
@article{Sun2025,
  author = {Sun, Jie and Lee, Kyunga and Kutseikin, Sergei and Guerrero, Adrian and Rius, Bibiana and Madhavan, Aparajita and Buasakdi, Chavin and Cheong, Ka-Neng and Chatterjee, Priyadarshini and Rosen, Dorian A and Yoon, Leonard and Ardejani, Maziar S and Mendoza, Alejandra and Rosarda, Jessica D and Saez, Enrique and Kelly, Jeffery W and Wiseman, R Luke},
  title = {Identification of a Selective Pharmacologic IRE1/XBP1s Activator with Enhanced Tissue Exposure},
  journal = {ACS Chemical Biology},
  year = {2025},
  doi = {10.1021/acschembio.4c00867}
}
Start for free →